Annual EBIT
$8.53 B
+$4.69 B+122.53%
31 December 2023
Summary:
AstraZeneca annual earnings before interest & taxes is currently $8.53 billion, with the most recent change of +$4.69 billion (+122.53%) on 31 December 2023. During the last 3 years, it has risen by +$3.34 billion (+64.32%). AZN annual EBIT is now -33.59% below its all-time high of $15.39 billion.AZN EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
$2.29 B
-$555.00 M-19.54%
30 September 2024
Summary:
AstraZeneca quarterly earnings before interest & taxes is currently $2.29 billion, with the most recent change of -$555.00 million (-19.54%) on 30 September 2024. Over the past year, it has increased by +$241.00 million (+11.79%). AZN quarterly EBIT is now -49.46% below its all-time high of $4.52 billion, reached on 31 March 1999.AZN Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
$9.64 B
+$241.00 M+2.56%
30 September 2024
Summary:
AstraZeneca TTM earnings before interest & taxes is currently $9.64 billion, with the most recent change of +$241.00 million (+2.56%) on 30 September 2024. Over the past year, it has increased by +$1.33 billion (+16.01%). AZN TTM EBIT is now -29.06% below its all-time high of $13.59 billion, reached on 30 September 2011.AZN TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AZN EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +122.5% | +11.8% | +16.0% |
| 3 y3 years | +64.3% | +237.2% | +245.8% |
| 5 y5 years | +153.8% | +199.9% | +183.4% |
AZN EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +743.2% | -28.9% | +237.2% | at high | +1875.9% |
| 5 y | 5 years | at high | +743.2% | -28.9% | +237.2% | at high | +1875.9% |
| alltime | all time | -33.6% | +1844.9% | -49.5% | +147.3% | -29.1% | +1875.9% |
AstraZeneca EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $2.29 B(-19.5%) | $9.64 B(+2.6%) |
| June 2024 | - | $2.84 B(-11.6%) | $9.40 B(+3.5%) |
| Mar 2024 | - | $3.21 B(+146.2%) | $9.08 B(+6.9%) |
| Dec 2023 | $8.53 B(+122.5%) | $1.30 B(-36.2%) | $8.49 B(+2.2%) |
| Sept 2023 | - | $2.04 B(-18.9%) | $8.31 B(+10.4%) |
| June 2023 | - | $2.52 B(-4.1%) | $7.53 B(+35.2%) |
| Mar 2023 | - | $2.63 B(+134.1%) | $5.57 B(+45.4%) |
| Dec 2022 | $3.83 B(+278.9%) | $1.12 B(-11.0%) | $3.83 B(+60.7%) |
| Sept 2022 | - | $1.26 B(+126.0%) | $2.38 B(-539.0%) |
| June 2022 | - | $558.00 M(-37.2%) | -$543.00 M(+4836.4%) |
| Mar 2022 | - | $889.00 M(-374.4%) | -$11.00 M(-101.1%) |
| Dec 2021 | $1.01 B(-80.5%) | -$324.00 M(-80.6%) | $1.01 B(-63.8%) |
| Sept 2021 | - | -$1.67 B(-252.8%) | $2.79 B(-50.5%) |
| June 2021 | - | $1.09 B(-43.0%) | $5.63 B(-3.4%) |
| Mar 2021 | - | $1.91 B(+31.4%) | $5.83 B(+12.4%) |
| Dec 2020 | $5.19 B(+75.9%) | $1.45 B(+23.5%) | $5.19 B(+20.8%) |
| Sept 2020 | - | $1.18 B(-8.8%) | $4.29 B(+10.7%) |
| June 2020 | - | $1.29 B(+1.8%) | $3.88 B(+25.5%) |
| Mar 2020 | - | $1.27 B(+125.8%) | $3.09 B(+4.8%) |
| Dec 2019 | $2.95 B(-12.2%) | $561.00 M(-26.4%) | $2.95 B(-13.3%) |
| Sept 2019 | - | $762.00 M(+51.8%) | $3.40 B(-2.3%) |
| June 2019 | - | $502.00 M(-55.4%) | $3.48 B(-7.6%) |
| Mar 2019 | - | $1.13 B(+10.9%) | $3.77 B(+12.1%) |
| Dec 2018 | $3.36 B(-6.4%) | $1.01 B(+20.6%) | $3.36 B(+15.3%) |
| Sept 2018 | - | $841.00 M(+6.9%) | $2.91 B(-10.0%) |
| June 2018 | - | $787.00 M(+9.8%) | $3.24 B(-4.5%) |
| Mar 2018 | - | $717.00 M(+26.2%) | $3.39 B(-5.7%) |
| Dec 2017 | $3.59 B(-27.1%) | $568.00 M(-51.2%) | $3.59 B(-35.3%) |
| Sept 2017 | - | $1.16 B(+23.8%) | $5.55 B(+2.5%) |
| June 2017 | - | $940.00 M(+2.0%) | $5.42 B(+13.1%) |
| Mar 2017 | - | $922.00 M(-63.5%) | $4.79 B(-2.6%) |
| Dec 2016 | $4.92 B(+19.7%) | $2.53 B(+145.2%) | $4.92 B(+42.6%) |
| Sept 2016 | - | $1.03 B(+230.4%) | $3.45 B(-4.1%) |
| June 2016 | - | $312.00 M(-70.2%) | $3.60 B(-14.7%) |
| Mar 2016 | - | $1.05 B(-0.9%) | $4.22 B(+2.7%) |
| Dec 2015 | $4.11 B(+86.0%) | $1.06 B(-10.1%) | $4.11 B(+50.5%) |
| Sept 2015 | - | $1.18 B(+26.0%) | $2.73 B(+29.3%) |
| June 2015 | - | $934.00 M(-0.5%) | $2.11 B(-8.1%) |
| Mar 2015 | - | $939.00 M(-393.4%) | $2.30 B(+4.0%) |
| Dec 2014 | $2.21 B(-41.2%) | -$320.00 M(-157.3%) | $2.21 B(+13.4%) |
| Sept 2014 | - | $558.00 M(-50.1%) | $1.95 B(-37.4%) |
| June 2014 | - | $1.12 B(+31.5%) | $3.11 B(-2.8%) |
| Mar 2014 | - | $851.00 M(-246.5%) | $3.20 B(-15.1%) |
| Dec 2013 | $3.76 B(-54.0%) | -$581.00 M(-133.8%) | $3.77 B(-40.2%) |
| Sept 2013 | - | $1.72 B(+42.5%) | $6.30 B(-6.6%) |
| June 2013 | - | $1.21 B(-14.9%) | $6.75 B(-9.1%) |
| Mar 2013 | - | $1.42 B(-27.4%) | $7.42 B(-9.2%) |
| Dec 2012 | $8.16 B(-36.4%) | $1.95 B(-9.7%) | $8.16 B(+2.1%) |
| Sept 2012 | - | $2.17 B(+15.2%) | $7.99 B(-22.0%) |
| June 2012 | - | $1.88 B(-13.3%) | $10.24 B(-10.7%) |
| Mar 2012 | - | $2.17 B(+21.5%) | $11.47 B(-10.7%) |
| Dec 2011 | $12.84 B(+7.0%) | $1.78 B(-59.6%) | $12.84 B(-5.6%) |
| Sept 2011 | - | $4.42 B(+42.4%) | $13.59 B(+16.1%) |
| June 2011 | - | $3.10 B(-12.4%) | $11.71 B(-0.5%) |
| Mar 2011 | - | $3.54 B(+39.3%) | $11.77 B(-2.0%) |
| Dec 2010 | $12.00 B(+1.2%) | $2.54 B(+0.4%) | $12.01 B(+2.0%) |
| Sept 2010 | - | $2.53 B(-20.0%) | $11.78 B(-6.4%) |
| June 2010 | - | $3.16 B(-16.3%) | $12.57 B(+1.7%) |
| Mar 2010 | - | $3.78 B(+63.5%) | $12.36 B(+4.2%) |
| Dec 2009 | $11.86 B(+18.6%) | $2.31 B(-30.6%) | $11.86 B(+1.7%) |
| Sept 2009 | - | $3.33 B(+13.0%) | $11.66 B(+5.2%) |
| June 2009 | - | $2.94 B(-10.1%) | $11.09 B(+3.0%) |
| Mar 2009 | - | $3.28 B(+55.3%) | $10.76 B(+7.6%) |
| Dec 2008 | $10.00 B | $2.11 B(-23.5%) | $10.00 B(+9.7%) |
| Sept 2008 | - | $2.76 B(+5.3%) | $9.12 B(+6.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2008 | - | $2.62 B(+4.1%) | $8.60 B(+4.9%) |
| Mar 2008 | - | $2.52 B(+105.1%) | $8.19 B(+1.2%) |
| Dec 2007 | $8.09 B(-1.5%) | $1.23 B(-45.2%) | $8.09 B(-1.9%) |
| Sept 2007 | - | $2.24 B(+1.2%) | $8.25 B(-1.1%) |
| June 2007 | - | $2.21 B(-8.5%) | $8.34 B(-3.7%) |
| Mar 2007 | - | $2.42 B(+74.9%) | $8.66 B(+5.4%) |
| Dec 2006 | $8.22 B(+26.4%) | $1.38 B(-40.6%) | $8.22 B(+2.9%) |
| Sept 2006 | - | $2.33 B(-8.1%) | $7.99 B(+2.7%) |
| June 2006 | - | $2.53 B(+28.1%) | $7.77 B(+12.6%) |
| Mar 2006 | - | $1.98 B(+71.5%) | $6.91 B(+6.2%) |
| Dec 2005 | $6.50 B(+43.0%) | $1.15 B(-45.5%) | $6.50 B(-1.8%) |
| Sept 2005 | - | $2.12 B(+27.2%) | $6.62 B(+16.6%) |
| June 2005 | - | $1.66 B(+5.8%) | $5.68 B(+12.1%) |
| Mar 2005 | - | $1.57 B(+23.7%) | $5.07 B(+10.7%) |
| Dec 2004 | $4.55 B(+13.5%) | $1.27 B(+8.4%) | $4.58 B(+15.0%) |
| Sept 2004 | - | $1.17 B(+11.4%) | $3.98 B(+1.5%) |
| June 2004 | - | $1.05 B(-3.0%) | $3.92 B(+3.3%) |
| Mar 2004 | - | $1.08 B(+60.8%) | $3.80 B(-5.3%) |
| Dec 2003 | $4.01 B(+0.0%) | $674.00 M(-39.4%) | $4.01 B(-0.8%) |
| Sept 2003 | - | $1.11 B(+20.3%) | $4.04 B(+4.5%) |
| June 2003 | - | $925.04 M(-28.6%) | $3.87 B(-3.5%) |
| Mar 2003 | - | $1.30 B(+83.1%) | $4.00 B(-0.0%) |
| Dec 2002 | $4.01 B(-3.6%) | $707.26 M(-24.6%) | $4.01 B(-8.7%) |
| Sept 2002 | - | $937.74 M(-11.9%) | $4.39 B(-1.7%) |
| June 2002 | - | $1.06 B(-18.0%) | $4.47 B(+2.9%) |
| Mar 2002 | - | $1.30 B(+19.0%) | $4.34 B(+5.0%) |
| Dec 2001 | $4.16 B(+4.4%) | $1.09 B(+7.4%) | $4.14 B(-1.0%) |
| Sept 2001 | - | $1.01 B(+8.0%) | $4.18 B(+2.1%) |
| June 2001 | - | $940.00 M(-13.9%) | $4.09 B(-1.1%) |
| Mar 2001 | - | $1.09 B(-3.7%) | $4.14 B(+4.0%) |
| Dec 2000 | $3.98 B(+16.1%) | $1.13 B(+22.0%) | $3.98 B(+18.8%) |
| Sept 2000 | - | $928.53 M(-6.0%) | $3.35 B(+0.6%) |
| June 2000 | - | $987.45 M(+5.9%) | $3.33 B(-0.6%) |
| Mar 2000 | - | $932.80 M(+85.1%) | $3.35 B(-51.7%) |
| Dec 1999 | $3.43 B(+41.3%) | $504.00 M(-44.5%) | $6.94 B(+332.0%) |
| Sept 1999 | - | $908.00 M(-10.0%) | $1.61 B(-47.0%) |
| June 1999 | - | $1.01 B(-77.7%) | $3.03 B(+12.0%) |
| Mar 1999 | - | $4.52 B(-193.6%) | $2.71 B(+350.0%) |
| Dec 1998 | $2.43 B(+28.6%) | -$4.83 B(-307.3%) | $601.10 M(-41.2%) |
| Sept 1998 | - | $2.33 B(+240.2%) | $1.02 B(+29.2%) |
| June 1998 | - | $685.00 M(-71.7%) | $791.55 M(-66.9%) |
| Mar 1998 | - | $2.42 B(-154.8%) | $2.39 B(+5.9%) |
| Dec 1997 | $1.89 B(+6.1%) | -$4.41 B(-310.1%) | $2.26 B(-40.9%) |
| Sept 1997 | - | $2.10 B(-8.1%) | $3.82 B(-5.3%) |
| June 1997 | - | $2.28 B(0.0%) | $4.03 B(+0.1%) |
| Mar 1997 | - | $2.28 B(-180.2%) | $4.03 B(+0.1%) |
| Dec 1996 | $1.78 B(+69.1%) | -$2.85 B(-223.1%) | $4.02 B(+89.9%) |
| Sept 1996 | - | $2.31 B(+1.5%) | $2.12 B(+21.8%) |
| June 1996 | - | $2.28 B(0.0%) | $1.74 B(-1184.3%) |
| Mar 1996 | - | $2.28 B(-147.9%) | -$160.41 M(-62.0%) |
| Dec 1995 | $1.05 B(-8.3%) | -$4.75 B(-345.6%) | -$421.81 M(-240.2%) |
| Sept 1995 | - | $1.94 B(+411.0%) | $300.94 M(+153.4%) |
| June 1995 | - | $378.70 M(-81.2%) | $118.74 M(-92.5%) |
| Mar 1995 | - | $2.02 B(-150.1%) | $1.58 B(+12.9%) |
| Dec 1994 | $1.15 B(+0.8%) | -$4.03 B(-329.9%) | $1.40 B(-8.8%) |
| Sept 1994 | - | $1.75 B(-4.6%) | $1.53 B(+16.4%) |
| June 1994 | - | $1.84 B(0.0%) | $1.32 B(+7.2%) |
| Mar 1994 | - | $1.84 B(-147.2%) | $1.23 B(+7.8%) |
| Dec 1993 | $1.14 B(+159.9%) | -$3.90 B(-353.4%) | $1.14 B(-77.4%) |
| Sept 1993 | - | $1.54 B(-12.1%) | $5.03 B(+44.0%) |
| June 1993 | - | $1.75 B(0.0%) | $3.50 B(+100.0%) |
| Mar 1993 | - | $1.75 B | $1.75 B |
| Dec 1992 | $438.32 M(-68.4%) | - | - |
| Dec 1991 | $1.39 B(+29.3%) | - | - |
| Dec 1990 | $1.07 B | - | - |
FAQ
- What is AstraZeneca annual earnings before interest & taxes?
- What is the all time high annual EBIT for AstraZeneca?
- What is AstraZeneca annual EBIT year-on-year change?
- What is AstraZeneca quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for AstraZeneca?
- What is AstraZeneca quarterly EBIT year-on-year change?
- What is AstraZeneca TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for AstraZeneca?
- What is AstraZeneca TTM EBIT year-on-year change?
What is AstraZeneca annual earnings before interest & taxes?
The current annual EBIT of AZN is $8.53 B
What is the all time high annual EBIT for AstraZeneca?
AstraZeneca all-time high annual earnings before interest & taxes is $15.39 B
What is AstraZeneca annual EBIT year-on-year change?
Over the past year, AZN annual earnings before interest & taxes has changed by +$4.69 B (+122.53%)
What is AstraZeneca quarterly earnings before interest & taxes?
The current quarterly EBIT of AZN is $2.29 B
What is the all time high quarterly EBIT for AstraZeneca?
AstraZeneca all-time high quarterly earnings before interest & taxes is $4.52 B
What is AstraZeneca quarterly EBIT year-on-year change?
Over the past year, AZN quarterly earnings before interest & taxes has changed by +$241.00 M (+11.79%)
What is AstraZeneca TTM earnings before interest & taxes?
The current TTM EBIT of AZN is $9.64 B
What is the all time high TTM EBIT for AstraZeneca?
AstraZeneca all-time high TTM earnings before interest & taxes is $13.59 B
What is AstraZeneca TTM EBIT year-on-year change?
Over the past year, AZN TTM earnings before interest & taxes has changed by +$1.33 B (+16.01%)